Clopidogrel

Description

Introducing PharmAlliance International Labs’ Clopidogrel Tablets

Company Introduction:

Welcome to PharmAlliance International Labs Private Limited, a renowned provider of premium pharmaceuticals dedicated to enhancing patient health worldwide. We take pride in introducing our flagship product, Clopidogrel Tablets, meticulously crafted to prevent cardiovascular events and promote heart health.

Drug Classification:

Clopidogrel belongs to the class of medications known as antiplatelet agents. It is a thienopyridine derivative that selectively inhibits the adenosine diphosphate (ADP) receptor on platelets, thereby preventing platelet aggregation and reducing the risk of blood clot formation.

Formulations:

PharmAlliance International Labs offers Clopidogrel Tablets in a standard strength of 75mg. These oral tablets are conveniently packaged in blister packs containing 20 tablets each, ensuring ease of administration.

Indications:

Clopidogrel Tablets are indicated for:

Prevention of atherothrombotic events in patients with acute coronary syndrome (unstable angina, non-ST segment elevation myocardial infarction [NSTEMI], or ST segment elevation myocardial infarction [STEMI]), including patients undergoing percutaneous coronary intervention (PCI).

Secondary prevention of atherothrombotic events in patients with a history of myocardial infarction, stroke, or peripheral arterial disease.

Usage:

Clopidogrel Tablets should be taken orally once daily, with or without food. Adherence to the prescribed dosage and administration instructions provided by a healthcare professional is crucial. Typically, Clopidogrel is used in combination with aspirin, unless contraindicated, to achieve optimal antiplatelet therapy.

Dosage:

The recommended dose of Clopidogrel is 75 mg once daily. For patients with acute coronary syndrome, a loading dose of 300mg may be administered initially, followed by the standard maintenance dose of 75mg daily. Dosage adjustments are not necessary based on age, gender, or renal impairment.

Pharmacokinetics:

Clopidogrel is rapidly absorbed after oral administration, with peak plasma concentrations achieved within 1 to 2 hours. It undergoes extensive hepatic metabolism to form its active metabolite, which is responsible for its antiplatelet effects. The active metabolite has a half-life of approximately 8 hours, allowing for once-daily dosing.

Pharmacodynamics:

Clopidogrel irreversibly binds to the P2Y12 subtype of the ADP receptor on platelets, inhibiting ADP-induced platelet aggregation and activation. By preventing platelet activation and aggregation, Clopidogrel reduces the risk of thrombotic events, including myocardial infarction, stroke, and cardiovascular death.

Side Effects:

Common side effects associated with Clopidogrel therapy may include gastrointestinal symptoms such as abdominal pain, diarrhea, and dyspepsia. Bleeding, including gastrointestinal and intracranial hemorrhage, is a known adverse effect and may occur with prolonged use of Clopidogrel. Rare but serious adverse effects such as thrombotic thrombocytopenic purpura (TTP) and neutropenia have been reported and require immediate medical attention.

Experience the proven efficacy and cardiovascular protection provided by PharmAlliance International Labs’ Clopidogrel Tablets. For more information, please contact us. Your heart health is our priority, and we are committed to providing you with safe and effective pharmaceutical solutions.